NASDAQ:ESLA
Estrella Immunopharma, Inc.
Estrella Immunopharma, Inc. reported net income of −$13.1M in fiscal 2025.Summary generated from Estrella Immunopharma, Inc.'s SEC filings. Latest annual report filed Mar 18, 2026.
Key statistics
Fiscal 2025 from SEC filings. MethodologyRevenue (FY25)n/a
Revenue growthn/a
Revenue, 5-yr CAGRn/a
Gross marginn/a
Operating marginn/a
Net marginn/a
ROICn/a
Return on equityn/a
Debt / equityn/a
Free cash flown/a
FCF marginn/a
Share count changen/a
Financials
| Item | 2021 | 2022 | 2025 |
|---|---|---|---|
| Revenue | n/a | n/a | n/a |
| Operating income | −0 | −2 | −13 |
| Net income | −0 | −1 | −13 |
| Free cash flow | n/a | n/a | n/a |
Recent filings
- 8-KNotice of delisting or listing-rule failure
Sep 8, 2026 - 4Insider transaction report
Aug 26, 2026 - 4Insider transaction report
Aug 25, 2026 - 8-KNotice of delisting or listing-rule failure
Aug 21, 2026 - 10-QQuarterly report for the period ended Jun 30, 2026
Aug 13, 2026 - 8-KResults of a shareholder vote
Jun 30, 2026 - DEF 14AProxy statement
May 27, 2026 - 10-QQuarterly report for the period ended Mar 31, 2026
May 18, 2026